By Annie Zeng
Gene therapy is an experimental and therapeutic technique involving the engineering of genes with the hope to cure disease at its root cause. This has become an increasingly buoyant area for investment and although still at an early phase of development, there have been recent approvals of clinical and commercial gene therapies for use in humans.
Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec to increase production of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale.
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing cell and gene therapy companies, strengthening the UK’s sectorial advantage and Hertfordshire’s position within the Oxford-London-Cambridge golden research triangle.
Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.
Brighton, UK, 15 October 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced it has been awarded up to £5.7M ($7M) funding under the Therapeutics Development Award programme from the Cystic Fibrosis Foundation.
Edinburgh-based biotechnology company MedAnnex today announced that cell line development for the generation of its anti-Annexin A1 antibodies is under way, at FUJIFILM Diosynth Biotechnologies’ (Fujifilm) Billingham, UK site.
Leading gene therapy manufacturer recognised as part of Oxfordshire Business Awards
Oxford, UK, June 18 2019 - Its work on life-changing treatments for serious diseases has earned Oxford Biomedica, a leading gene and cell therapy group, The Oxford Science Park Innovation Award 2019.